Combination (I) comprises a phosphodiesterase inhibitor 4 (PDE4) (A) and an antagonist of M3 muscarinic receptors (B) (3(R)-(2-hydroxy-2, 2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo [2.2.2] octane), in the form of a salt having an anion X (anion of a mono or polyvalent acid). An independent claim is also included for a method of treating a patient suffering from or susceptible to a respiratory disease or condition which responds to M3 antagonism comprising simultaneous, concurrent, separate or sequential administration of (I). ACTIVITY : Antiasthmatic； Respiratory-Gen.； Antiinflammatory. MECHANISM OF ACTION : Phosphodiesterase-4 inhibitor； Muscarinic receptors antagonist； Leukotriene-D4 antagonist； Neurokinin-1- receptor antagonist； Epidermal growth factor receptor kinase inhibitor； Beta-2 agonist； p38 Kinase inhibitor.本發明係關於特定之抗蕈毒鹼劑及β-腎上腺素激動劑之新穎的組合及其在治療呼吸失調之用途。
